Windlas

Gurugram, India Founded: 2001 • Age: 25 yrs Listed Acquired By Zydus Life
Biopharma regulatory affairs, quality control, and strategy services are provided.
Request Access
Report Incorrect Data
Page last updated

About Windlas

Windlas is a publicly listed company based in Gurugram (India) founded in 2001 by Ashok Kumar Windlas and Manoj Kumar Windlass, and was acquired by Zydus Life in August 2018. Biopharma regulatory affairs, quality control, and strategy services are provided. Windlas has raised $12.96 million across 3 funding rounds from investors including HDFC Bank, HSBC and Kotak Mahindra Bank. The company has 895 employees. Windlas was last valued at $81.22 million in August 2015. Its chief executive, as recorded, is Komal Gupta. Its Indian entity Windlas Biotech Limited reported revenue of ₹922 Cr. Windlas offers products and services including Contract Manufacturing Services, Therapeutic Products, and Customized Formulations. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed competitors have raised funding.

Company details

Windlas was founded in 2001 and is headquartered in Gurugram, India. Regulatory affairs, quality control, and market strategy services are delivered to the biopharma sector by the company. Operations focus on supporting biopharma firms with compliance, testing, and strategic planning needs. Leadership includes co-founders Ashok Kumar Windlas and Manoj Kumar Windlass, alongside CEO Komal Gupta, whose details encompass DIN and PAN identifiers for corporate records.

  • Headquarters Gurugram, India
  • Employees 895
  • Founders Ashok Kumar Windlas, Manoj Kumar Windlass
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website windlas.com
  • Social LinkedIn X Facebook Instagram
  • Acquired by Zydus Life (Aug 2018)
  • Legal Name Windlas Biotech Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹2,010 Cr

    WINDLAS · NSE

  • Share Price
    ₹974.25

    -4.34% today

  • Revenue
    ₹904 Cr

    FY 2025-26 · +19.0% YoY

  • EBITDA
    ₹105 Cr

    Margin 11.6%

  • Net Profit
    ₹66.46 Cr

    FY 2025-26 · +9.0% YoY

  • P/E (TTM)
    31.6x

    P/B 3.6x

  • ROE
    12.2%

    ROCE 15.8%

  • Debt / Equity
    0.06

    Interest cover 6.5x

  • Total Equity Funding
    $12.96M (USD)

    in 3 rounds

  • Latest Funding Round
    $2.45M (USD), Debt – Conventional

    Jun 2021

  • Investors
    HDFC Bank

    & 5 more

  • Employee Count
    895
  • Acquired by
    Zydus Life

    (Aug 2018)

Products & Services of Windlas

Windlas offers a comprehensive portfolio of products and services, including Contract Manufacturing Services, Therapeutic Products, and Customized Formulations.

Contract Manufacturing Services
Manufacturing

Provides contract development and production for pharmaceuticals

Therapeutic Products
Pharmaceuticals

Offers formulations for health conditions like anti-diabetic and cardiovascular

Customized Formulations
Research Services

Delivers tailored pharmaceutical solutions for clients

Funding Insights of Windlas

Windlas has successfully raised a total of $12.96M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $2.45 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $12.96M
  • Total Rounds 3
  • Last Round Debt – Conventional — $2.45M
  • First Round $12.96M

    (Aug 2015)

  • Investors Count 5

All 3 funding rounds of Windlas with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2021$2.45MDebt – Conventional––
HDFC Bank, HSBC
Apr 2021$6.13MDebt – Conventional––
IndusInd Bank, HSBC
Aug 2015$12.96MPrivate Equity Round$81.22MTano Capital
–
Valuation history
DateValuationStage
Aug 2015$81.22M••••••••

Last known valuation $81.22M (Aug 2015). 6 investors in total: 6 institutional.

Investors in Windlas

Windlas has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include HDFC Bank, HSBC and Kotak Mahindra Bank.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
HDFC Bank
Commercial and personal banking services are offered by HDFC Bank.
1994hdfcbank.comMumbai, India
HSBC
Universal banking and financial advisory services are provided globally.
1865hsbc.comLondon, United Kingdom
IndusInd Bank
Personal and business banking products and services are provided.
1994indusind.comPune, India
Kotak Mahindra Bank
Commercial banking services are offered to corporate and retail customers.
1985kotak.comMumbai, India
Tano Capital
Provider of asset management services
tanocapital.comSan Francisco, United States
Zydus Life
Manufacturer of pharmaceutical products, including formulations, APIs, vaccines, and biosimilars
1952zyduslife.comAhmedabad, India
Premium access

Investor details for Windlas

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Windlas Biotech Limited (Windlas)

Windlas Biotech Limited is the primary company behind Windlas. The boards of the 2 registered companies of Windlas currently have 11 directors; the longest-serving is Ashok Kumar Windlass, appointed in 2001. 30 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ashok Kumar Windlass
DIN 00011451
Whole-time director19 Feb 200125 yrs 8 moWindlas Biotech Limited
Manoj Kumar Windlass
DIN 00221671
Managing Director01 Apr 200620 yrs 7 moWindlas Biotech Limited
Hitesh Windlass
DIN 02030941
Person Incharge17 Jul 201511 yrs 3 moWindlas Healthcare Private Limited, Windlas Biotech Limited
Pawan Kumar Sharma
DIN 08478261
Whole-time director11 Jun 20197 yrs 5 moWindlas Biotech Limited
Ashok Sharma
DIN 08734674
Director17 Apr 20206 yrs 6 moWindlas Healthcare Private Limited
Chander Prakash
DIN 08347603
Director17 Apr 20206 yrs 6 moWindlas Healthcare Private Limited
Ashish Jain
DIN 03495680
Director17 Apr 20206 yrs 6 moWindlas Healthcare Private Limited
Prachi Jain Windlass
DIN 06661073
Director03 May 20215 yrs 6 moWindlas Biotech Limited
Vivek Dhariwal
DIN 02826679
Director06 May 20215 yrs 6 moWindlas Biotech Limited
Gaurav Gulati
DIN 02308392
Director06 May 20215 yrs 6 moWindlas Biotech Limited
Tarashree Singhal
DIN 11697518
Additional Director05 May 20266 moWindlas Biotech Limited

People of Windlas

3 people are tracked at Windlas (3 in leadership); the tracked headcount is 895.

NameRoleGroup
Ashok Kumar Windlas
Co-FounderLeadership
Manoj Kumar Windlass
Co-FounderLeadership
Komal Gupta
CEOLeadership
Premium access

Complete people profiles for Windlas

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Windlas

Windlas is a publicly listed company on the NSE with ticker symbol WINDLAS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 Aug 2021
  • Listed onBSE: 543329 · NSE: WINDLAS
  • Listed entityWindlas Biotech Ltd.
  • Exchange sectorHealth technology
  • ISININE0H5O01029
  • Share price₹923.50 (-1.25% on the day) · 2026-10-14
  • Market capitalisation₹1,929 Cr
  • Price to earnings29.5
  • EPS (diluted, trailing year)₹31.26
  • Dividend yield0.66%
  • Volume (last session)38,445

Financials of Windlas

Exchange-reported figures of Windlas Biotech Limited, the listed company behind Windlas (NSE: WINDLAS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹904 Cr
+19.0% YoY
EBITDA
₹105 Cr
+11.3% YoY
Profit After Tax
₹66.46 Cr
+9.0% YoY
Net Worth
₹581 Cr
+14.8% YoY
Total Assets
₹620 Cr
+14.4% YoY
Total Debt
₹35.25 Cr
+8.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue904760631513466428329
Revenue growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
EBITDA10594.1078.1760.2352.4127.2634.00
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.3%+6.4%+10.3%
Profit before tax86.9879.7577.0957.0545.5521.7424.67
Net profit66.4660.9858.1841.9938.0731.3116.23
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.2%+7.3%+4.9%
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
Balance sheet
Total assets620541456410403233240
Net worth581506450402395199210
Total debt35.2532.603.644.996.6432.3528.93
Cash & bank1.8115.9330.9525.4511431.1118.38
Net working capital70.6482.6687.7312822910947.15
Cash flow
Cash from operations10568.1910960.979.1311.4625.01
Cash from investing(91.79)(74.06)(92.07)(14.11)(155)(20.20)(14.34)
Cash from financing(13.03)1.01(15.29)(43.74)1300.78(5.44)
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue238233222210203195187175
Revenue growth (YoY)+17.7%+19.5%+18.9%+20.0%+18.3%---
Other income4.354.573.655.244.944.114.844.13
EBITDA25.2924.3728.5626.5225.5524.6323.0520.88
EBITDA margin+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%+11.9%
Depreciation8.007.707.607.458.346.946.506.21
Interest1.481.281.021.061.331.461.100.49
Profit before tax20.1619.9623.5923.2520.8220.3420.2918.31
Tax4.184.975.795.594.554.764.634.83
Net profit15.9814.9917.8017.6616.2715.5815.6613.48
EPS (₹)7.497.058.408.347.697.387.436.47
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue904760631513466428329
Revenue growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
EBITDA10594.1178.1060.2552.8822.3440.67
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.4%+5.2%+12.4%
Profit before tax86.9479.3977.0357.0746.0211.1730.57
Net profit66.4460.6458.1542.0138.5419.4922.46
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.3%+4.6%+6.8%
EPS (₹)31.4828.9427.9620.3817.697.8135.03
Balance sheet
Total assets620541456410404233245
Net worth581506450403395199216
Total debt35.2532.603.644.996.6432.3527.43
Cash & bank1.8115.9230.9025.4511430.9618.38
Net working capital70.6482.9788.0812822910947.67
Cash flow
Cash from operations10568.2310960.989.0011.4520.87
Cash from investing(91.79)(74.06)(92.07)(14.11)(154)(20.19)(9.16)
Cash from financing(13.03)1.01(15.29)(43.74)1300.78(6.48)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue264248238233222210203195
Revenue growth (YoY)+18.7%+18.1%+17.7%+19.5%+18.9%+20.0%--
Other income3.865.114.404.523.655.244.943.73
Total expenses235221213209194184177170
EBITDA29.3726.6825.2424.3728.5626.5225.5524.64
EBITDA margin+11.1%+10.8%+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%
Depreciation7.597.218.007.707.607.458.346.94
Interest2.331.651.481.281.021.061.331.46
Profit before tax23.3122.9320.1619.9123.5923.2520.8219.97
Tax5.255.284.154.975.795.594.554.74

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue238233222210203195187175
Revenue growth (YoY)+17.7%+19.5%+18.9%+20.0%+18.3%---
Other income4.354.573.655.244.944.114.844.13
EBITDA25.2924.3728.5626.5225.5524.6323.0520.88
EBITDA margin+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%+12.3%+11.9%
Depreciation8.007.707.607.458.346.946.506.21
Interest1.481.281.021.061.331.461.100.49
Profit before tax20.1619.9623.5923.2520.8220.3420.2918.31
Tax4.184.975.795.594.554.764.634.83
Net profit15.9814.9917.8017.6616.2715.5815.6613.48
EPS (₹)7.497.058.408.347.697.387.436.47
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue904760631513466428329
Revenue growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
Other income17.8018.0213.479.976.718.742.49
Total expenses799666553453414400295
Employee cost15212387.4670.3263.4158.3243.57
EBITDA10594.1078.1760.2352.4127.2634.00
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.3%+6.4%+10.3%
Depreciation30.7427.9913.4412.3612.1512.979.29
Interest4.834.381.110.791.421.292.53
Profit before tax86.9879.7577.0957.0545.5521.7424.67
Tax20.5218.7618.9114.417.476.178.45
Net profit66.4660.9858.1841.9938.0731.3116.23
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.2%+7.3%+4.9%
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5510.4810.4010.4610.906.416.41
Reserves & surplus570495440392384193203
Shareholders' funds (net worth)581506450402395199210
Minority interest0.000.000.000.000.000.000.00
Secured loans29.8827.120.110.445.7630.2427.43
Unsecured loans5.375.483.534.550.882.111.50
Total debt35.2532.603.644.996.6432.3528.93
Total liabilities620541456410403233240
Assets
Gross block36734727519416415779.35
Net block21322317910991.1895.9470.26
Capital work in progress59.595.325.7114.788.010.040.00
Investments26822317310764.8223.14116
Inventories61.8281.3862.1974.7458.7141.4649.32
Sundry debtors22716713611711179.4163.94
Cash & bank balances1.8115.9330.9525.4511431.1118.38
Loans & advances67.4437.5928.4429.9733.5219.1914.11
Total current assets358302258247317171146
Total current liabilities28821917011987.7962.4198.60
Net working capital70.6482.6687.7312822910947.15
Total assets620541456410403233240
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.425.293.690.5715.9323.9012.86
Net cash from operating activities10568.1910960.979.1311.4625.01
Net cash from investing activities(91.79)(74.06)(92.07)(14.11)(155)(20.20)(14.34)
Net cash from financing activities(13.03)1.01(15.29)(43.74)1300.78(5.44)
Net change in cash0.11(4.86)1.603.12(15.36)(7.97)5.22
Closing cash1.8115.9330.9525.4511431.1118.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
EBITDA growth+11.3%+20.4%+29.8%+14.9%+92.3%-19.8%-
PBT growth+9.1%+3.5%+35.1%+25.3%+109.5%-11.9%-67.6%
Net income growth+9.0%+4.8%+38.6%+10.3%+21.6%+92.9%-
Revenue CAGR (3Y)+20.8%+17.7%+13.9%+16.0%+14.9%+6.7%-
EBITDA CAGR (3Y)+20.3%+21.5%+42.1%+21.0%+11.6%-11.5%-
Profitability & leverage
Net income margin+7.4%+8.0%+9.2%+8.3%+8.2%+3.6%+4.9%
Return on capital employed+15.8%+16.9%+18.1%+14.2%+14.8%+18.9%+11.7%
Return on net worth+12.2%+12.8%+13.7%+10.7%+12.8%+15.2%+8.0%
Debt / equity0.060.040.010.010.070.150.15
Long-term debt / equity0.000.000.010.000.000.010.02
Interest cover6.536.631.711.653.539.0310.24
Efficiency & per share
Fixed asset turnover2.542.452.692.872.903.624.01
Inventory turnover12.6310.599.227.699.309.429.62
Debtors turnover4.595.014.994.514.905.975.23
EPS (₹)31.4929.1027.9820.3717.4824.7025.29
Dividend per share (₹)6.305.805.504.003.500.000.00
Book value per share (₹)275.20241.30216.34192.24181.14310.59327.03
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue264248238233222210203195
Revenue growth (YoY)+18.7%+18.1%+17.7%+19.5%+18.9%+20.0%--
Other income3.865.114.404.523.655.244.943.73
Total expenses235221213209194184177170
EBITDA29.3726.6825.2424.3728.5626.5225.5524.64
EBITDA margin+11.1%+10.8%+10.6%+10.5%+12.8%+12.6%+12.6%+12.6%
Depreciation7.597.218.007.707.607.458.346.94
Interest2.331.651.481.281.021.061.331.46
Profit before tax23.3122.9320.1619.9123.5923.2520.8219.97
Tax5.255.284.154.975.795.594.554.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue904760631513466428329
Revenue growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
Other income17.8017.6513.479.976.713.090.96
Total expenses799666553453413405288
Employee cost15212387.4670.3263.4158.3243.88
EBITDA10594.1178.1060.2552.8822.3440.67
EBITDA margin+11.6%+12.4%+12.4%+11.7%+11.4%+5.2%+12.4%
Depreciation30.7427.9913.4412.3612.1512.978.69
Interest4.834.381.100.791.421.292.37
Profit before tax86.9479.3977.0357.0746.0211.1730.57
Tax20.5018.7418.8814.417.476.178.11
Net profit66.4460.6458.1542.0138.5419.4922.46
Net profit margin+7.4%+8.0%+9.2%+8.2%+8.3%+4.6%+6.8%
EPS (₹)31.4828.9427.9620.3817.697.8135.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5510.4810.4010.4610.906.416.41
Reserves & surplus570495440392384193210
Shareholders' funds (net worth)581506450403395199216
Secured loans29.8827.120.110.446.1230.2422.16
Unsecured loans5.375.483.534.550.522.115.27
Total debt35.2532.603.644.996.6432.3527.43
Total liabilities620541456410404233245
Assets
Gross block367346274193164157141
Net block21322317910991.1895.9468.43
Capital work in progress59.595.325.7114.788.010.040.00
Investments26822317310764.8623.18121
Inventories61.8281.3862.1974.7458.7141.4649.32
Sundry debtors22716713611711179.4164.56
Cash & bank balances1.8115.9230.9025.4511430.9618.38
Loans & advances67.4437.8928.4429.9733.5219.1814.11
Total current assets358302258247317171146
Total current liabilities28821917011987.4662.4298.70
Net working capital70.6482.9788.0812822910947.67
Total assets620541456410404233245
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.425.243.690.5515.7823.7412.86
Net cash from operating activities10568.2310960.989.0011.4520.87
Net cash from investing activities(91.79)(74.06)(92.07)(14.11)(154)(20.19)(9.16)
Net cash from financing activities(13.03)1.01(15.29)(43.74)1300.78(6.48)
Net change in cash0.11(4.82)1.563.13(15.22)(7.97)5.22
Closing cash1.8115.9230.9025.4511430.9618.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.0%+20.4%+23.0%+10.1%+9.0%+30.0%-
EBITDA growth+11.3%+20.5%+29.6%+13.9%+136.7%-45.1%-
PBT growth+9.5%+3.1%+35.0%+24.0%+312.0%-63.5%-12.3%
Net income growth+9.6%+4.3%+38.4%+9.0%+97.7%-13.2%-
Revenue CAGR (3Y)+20.8%+17.7%+13.9%+16.0%+17.4%+10.1%+1.4%
EBITDA CAGR (3Y)+20.2%+21.2%+51.8%+14.0%+6.0%-16.5%+17.9%
Profitability & leverage
Net income margin+7.4%+8.0%+9.2%+8.3%+8.3%+1.2%+6.8%
Return on capital employed+15.8%+16.8%+18.0%+14.2%+14.9%+18.8%+14.0%
Return on net worth+12.2%+12.7%+13.6%+10.7%+13.0%+9.4%+10.9%
Debt / equity0.060.040.010.010.070.140.14
Long-term debt / equity0.000.000.010.000.000.010.02
Interest cover6.536.621.701.653.4913.777.41
Efficiency & per share
Fixed asset turnover2.542.452.702.872.902.872.47
Inventory turnover12.6310.599.227.699.309.429.62
Debtors turnover4.595.014.994.514.905.945.19
EPS (₹)31.4828.9427.9620.3817.697.8135.03
Dividend per share (₹)6.305.805.504.003.500.000.00
Book value per share (₹)275.20241.31216.51192.42181.30310.39337.66

Timeline of Windlas

6 dated milestones of Windlas across 20 years, from founding to its latest funding, stage changes and deals.

  1. Founded Windlas is founded.
  2. Funding First funding round of $13.0M.
  3. Milestone Reaches Minicorn status.
  4. Exit Acquired by Zydus Life.
  5. Funding Latest funding round, Debt – Conventional, of $2.5M.
  6. IPO Lists on the stock exchange (IPO).

Competitors of Windlas

Windlas has 3 listed competitors in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Akums
akums.in2004Delhi, India$70M395
CDMO focusing on spectrum of dosage forms and therapeutic segments
Jubilant Life Sciences
jubl.com1978Noida, India
Company offering a suite of R&D and manufacturing services for small molecules and generics
Nectar Lifesciences
neclife.com1995Chandigarh, India$46.85M175
Cephalosporin APIs and generic formulations are manufactured.
Premium access

Detailed competitors of Windlas

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Windlas

The website of Windlas (windlas.com) receives about 7.2K visits a month.

  • Monthly visits
    7.2K

    ▲ 20.4% vs previous month

Similar websites

Websites whose visitors overlap most with Windlas. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Value Research
valueresearchonline.com
100%
4.3M#12,646View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Windlas (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M548
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Windlas

WINDLAS: Q2 STANDALONE NET PROFIT 180.5M RUPEES VS 178M (YOY)
Exchange Update • 5 days ago
WINDLAS: Q2 REVENUE 2.64B RUPEES VS 2.22B (YOY)
Exchange Update • 5 days ago
WINDLAS: Q2 EBITDA 293.7M RUPEES VS 285.6M (YOY); Q2 EBITDA MARGIN 11.13% VS 12.84% (YOY)
Exchange Update • 5 days ago
Volume shocker stocks: Why share price of EMS, Expleo Solutions, Windlas Biotech, AKI India, Heritage Foods are up today
Mint • 2 months ago
Volume shocker stocks: Why share price of EMS, Expleo Solutions, Windlas Biotech, AKI India, Heritage Foods are up today | Stock Market News
mint • 2 months ago
Windlas Biotech Ltd June-Quarter Profit 176.5 Million Rupees
Reuters • 3 months ago
Windlas Biotech Approves Buyback Of Shares Worth Up To 470 Million Rupees
Reuters • 6 months ago
Windlas Biotech Dec-Quarter Consol Net Profit 150 Million Rupees
Reuters • 9 months ago
Windlas Biotech to Hold Analyst/Investor Meeting on September 3, 2025
Moneycontrol • 1 year ago
Windlas Biotech June-Quarter Consol Net Profit 176.6 Million Rupees
Reuters • 1 year ago
Premium access

Complete news archive for Windlas

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Windlas

Windlas was founded in 2001 and raised its 1st funding round 14 years after it was founded.

Windlas is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.

Komal Gupta is the CEO of Windlas, as recorded in our data.

Windlas is a funded company, having raised a total of $12.96M across 3 funding rounds to date. The company's 1st funding round was a Private Equity Round of $12.96M, raised on Aug 2015.

Windlas has 895 employees.

The primary company behind Windlas, Windlas Biotech Limited, reported revenue of ₹922 Cr for FY 2026, up 19% year on year.

Windlas was founded in 2001 and is headquartered in Gurugram, India. Regulatory affairs, quality control, and market strategy services are delivered to the biopharma sector by the company. Operations focus on supporting biopharma firms with compliance, testing, and strategic planning needs. Leadership includes co-founders Ashok Kumar Windlas and Manoj Kumar Windlass, alongside CEO Komal Gupta, whose details encompass DIN and PAN identifiers for corporate records.

Windlas's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Windlas offers Contract Manufacturing Services, Therapeutic Products, and Customized Formulations.

Yes, Windlas is publicly traded on NSE under the ticker symbol WINDLAS.

Windlas has 6 investors. Key investors include HDFC Bank, HSBC, Kotak Mahindra Bank, IndusInd Bank, and Zydus Life.

The valuation of Windlas is $81.22M as of Aug 2015.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available